Truist cuts target for Integra LifeSciences stock from USD 19 to USD 15
Published on 10/20/2026 at 22:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and operating dates
- Truist cut its target from USD 19.00 to USD 15.00 on October 14, 2026.
- Integra priced USD 450.00 million of senior secured notes on October 12, 2026.
- Integra LifeSciences stock costs EUR 11.85 at Lang & Schwarz on October 20, 2026 at 10:09 p.m. CEST.
- Third-quarter results are scheduled for October 21, 2026.
Integra LifeSciences (ISIN US4579852082) faces a lower analyst valuation before its third-quarter report, while Truist cut its target from USD 19.00 to USD 15.00. Markets Insider reported the change on October 14, 2026. At Lang & Schwarz, the stock stood at EUR 11.85 on October 20, 2026 at 10:09 p.m. CEST in after-hours trading.
USD 450 million refinancing
Integra also priced USD 450.00 million of senior secured notes due 2033 on October 12, 2026. MarketScreener listed the financing alongside the company's October refinancing activity. The debt transaction gives investors a second balance-sheet figure to weigh against the reduced target.
USD 8.70 to USD 20.49 range
The Nasdaq-listed stock last traded at USD 13.33 on October 20, 2026 at 4:00 p.m. ET in after-hours status. Its 52-week range was USD 8.70 to USD 20.49, while market capitalization stood at USD 1.0 billion and volume reached 1,296,962 shares.
The USD 15.00 Truist target is 12.56 percent above the USD 13.33 Nasdaq price. The comparison uses the same home-currency values and shows that the revised target still sits above the latest US quotation, even as the target itself was reduced by USD 4.00, or 21.05 percent, from USD 19.00.
USD 410 million to USD 412 million guidance
Integra's October 2 release projected third-quarter revenue of USD 410 million to USD 412 million and adjusted earnings per diluted share of USD 0.55 to USD 0.59. The release also lowered full-year revenue guidance to USD 1.634 billion to USD 1.654 billion from USD 1.654 billion to USD 1.695 billion, and adjusted earnings guidance to USD 2.30 to USD 2.40 from USD 2.40 to USD 2.50. Integra LifeSciences attributed the revisions to the July flooding event at its Cincinnati facility.
Third-quarter results are scheduled for October 21, 2026, according to the company's investor calendar. The company reported second-quarter revenue of USD 418.76 million for the period ended June 30, 2026, with net income of USD 4.48 million, according to its published press-release archive.
Target cut meets the next report
The reduced target and the scheduled report create a narrow investor checkpoint: the October 21 figures will test the USD 410 million to USD 412 million preliminary revenue range against the second-quarter revenue base of USD 418.76 million. The US quotation, the 52-week range and the financing amount provide the measurable backdrop.
The further course of trading is shown by the continuously updated real-time quote of Integra LifeSciences stock.
Integra LifeSciences market facts
- Company: Integra LifeSciences Holdings Corporation
- ISIN: US4579852082
- Ticker: IART
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 10:09 p.m. CEST): EUR 11.85
- Market capitalization: USD 1.0 billion (as of October 20, 2026)
- 52-week range: USD 8.70-20.49 (as of October 20, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: October 21, 2026
Market context: Market report Nasdaq Composite.
